

Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Debika Bhattacharya,^{1,6} Andrew Aronsohn,² Jennifer Price,³ and Vincent Lo Re III⁴; the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel^a

¹Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at the University of California–Los Angeles, Los Angeles, California, USA; ²Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois, USA; ³Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA; and ⁴Department of Medicine, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically reviews evidence from the field and update existing recommendations or introduce new recommendations as evidence warrants.

This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and retreatment recommendations for children as young as 3 years; management and treatment recommendations in the transplantation setting; and screening, treatment, and management recommendations for unique and key populations.

Keywords. HCV screening; direct-acting antivirals; HCV guidance; HCV treatment; HCV prevention.

The Infectious Diseases Society of America (IDSA) and the American Association for the Study of Liver Diseases (AASLD) collaboratively initiated the Hepatitis C Virus (HCV) Guidance Project in 2013 to provide clinicians with evidence-based, unbiased, timely guidance regarding diagnosis, treatment, and management of HCV infection. The project includes the web-based HCV guidance platform (www.hcvguidelines.org) to enable rapid, accessible dissemination of new and/or updated information and recommendations in response to the latest data from the field. The HCV guidance

website (hereafter, the HCV guidance) has been highly successful. From the launch of the HCV guidance in January 2014 through April 2022, the site has been accessed by more than 2 million unique users generating more than 4 million page views. In 2021, the site had more the 194 000 unique users from 201 countries and territories, with most visits originating from the United States, India, Russia, Canada, and Pakistan. Under the umbrella of the HCV guidance, the AASLD-IDSA HCV Guidance Panel (hereafter, the Guidance Panel) also issues regular, periodic published updates to review new or updated data and recommendations as well as an overview of the ever-changing landscape of the HCV epidemic.

Recognizing that viral hepatitis poses a public health threat on par with human immunodeficiency virus (HIV), malaria, and tuberculosis, in June 2016, the World Health Organization (WHO) published its first global health sector strategy and set forth the goal of elimination of viral hepatitis as a major public health threat by 2030 [1]. Specific HCV elimination targets include a 90% reduction in incidence and prevalence, treatment of 80% of eligible persons with chronic infection, a 65% reduction in HCV-related deaths, and universal access to key prevention and treatment services [1]. In response to the WHO's call to action, the National Academies

Received 08 May 2023; editorial decision 11 May 2023; published online 25 May 2023

^aHCV Guidance Panel members and their affiliations are listed in the Notes Section.

Correspondence: D. Bhattacharya, Department of Medicine, Division of Infectious Diseases, University of California Los Angeles David Geffen School of Medicine, 911 Broxton Avenue, Suite 200, Los Angeles, CA 90024 (debikab@mednet.ucla.edu). V. Lo Re III, Department of Medicine, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Center for Clinical Epidemiology and Biostatistics, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 (vincentl@penmedicine.upenn.edu).

Clinical Infectious Diseases[®]

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

<https://doi.org/10.1093/cid/ciad319>

- Universal HCV screening is recommended.
- The simplified HCV treatment algorithm now includes persons living with HIV.
- A new algorithm for incomplete treatment adherence is included with a key recommendation for persons who have missed ≤ 7 days of DAA therapy.
- HCV treatment is recommended for infected persons residing in jail or prison.
- Emerging data highlight the safety and efficacy of HCV DAA treatment in persons who have undergone solid organ transplantation.

Figure 1. Key points in HCV guidance summary. Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

of Sciences, Engineering, and Medicine developed a US strategic plan for viral hepatitis elimination [2]. The US Centers for Disease Control and Prevention (CDC) [3] and the US Department of Health and Human Services (DHHS) [4] subsequently developed national implementation strategies and targets commensurate with those set forth by the WHO. Notably, the new and updated recommendations highlighted and discussed in this update both independently and collectively support, promote, and advance accomplishment of HCV elimination.

Major changes in the HCV guidance since the previous 2020 publication [5] featured in this update include an ongoing emphasis on universal HCV screening; new recommendations that address the management of incomplete treatment adherence; updated recommendations regarding simplified treatment with minimal monitoring and expanded eligibility; management and treatment recommendations for solid organ transplant recipients; newly expanded treatment and retreatment recommendations for children and adolescents; and screening, management, and treatment recommendations for unique and key populations. In addition, we highlight key issues critical to HCV management with the mission of HCV elimination in mind. See Figure 1 for key points in this HCV guidance update.

PROCESS

The HCV guidance was developed and is regularly updated by a volunteer panel of more than 30 infectious diseases and hepatology clinicians and investigators with HCV expertise representing IDSA and AASLD, respectively. Four co-chairs (2 from each society) oversee the work of the Guidance Panel. The HCV guidance undergoes major biannual updates based on a rigorous literature review that encompasses peer-reviewed, published literature and relevant abstracts from national and international scientific conferences. The data are reviewed by section leads, with points of discussion resolved during section and full panel remote meetings.

New or updated recommendations are evaluated using a modified scale adapted from the American College of Cardiology and the American Heart Association practice guidelines [6, 7] (see the HCV guidance for further details). All new and updated recommendations are reviewed and approved by the IDSA and AASLD governing boards prior to on-line release or print publication.

TESTING, EVALUATION, AND MONITORING

Implementation of Universal HCV Screening

The Guidance Panel first recommended universal HCV screening for all adults aged ≥ 18 years in 2019 [5], concomitant with congruous draft recommendations from the US Preventive Services Task Force (USPSTF) and the CDC. The USPSTF subsequently recommended universal HCV screening for adults aged 18 to 79 years in March 2020 [8]. In April 2020, the CDC recommended HCV screening at least once in all adults aged ≥ 18 years and for all pregnant persons during each pregnancy, except in settings where HCV prevalence is $< 0.1\%$ [9]. The rationale for universal HCV screening includes cost-effectiveness [10–13]; improved HCV case finding [8, 9]; shifting epidemiology of HCV infection with incident infections occurring primarily in young adults [14–16]; and the availability of safe, cost-effective direct-acting antiviral (DAA) treatment [17]. Universal screening is a crucial and necessary component of any HCV elimination strategy [1–4] because it is the entry point into the HCV continuum of care [18, 19]. For initial HCV testing, the Guidance Panel recommends HCV antibody screening with reflex HCV RNA testing to establish the presence of active infection (as opposed to spontaneous or treatment-induced viral clearance).

Recommendations without rigorous implementation, however, are ineffectual. HCV screening, diagnosis, and treatment were significantly adversely affected by the coronavirus disease 2019 (COVID-19) pandemic [20]. The number of HCV antibody and HCV RNA tests processed by a large US, multicenter, commercial clinical laboratory decreased precipitously beginning in mid-March 2020 [21], coincident with the US federal government declaring a national state of emergency due to COVID-19 [22]. HCV RNA-positive test results decreased 62% in March 2020 and remained 39% below baseline in July 2020, with a concomitant decline in the number of DAA prescriptions dispensed [21]. Investigators who conducted a similar study in Ontario, Canada, reported comparable decreases in HCV antibody screening and confirmative HCV RNA testing during each of the first 3 waves of the COVID-19 pandemic [23]. The reduced level of HCV testing negatively affecting initiation of HCV treatment appears corroborated by findings from a US national, retrospective study wherein only 23% of people on Medicaid with a positive HCV RNA test between 30 January 2019 and 31 October 2020 initiated DAA treatment




Figure 2. Recommended management of DAA treatment interruptions for treatment-naive patients without cirrhosis or with compensated cirrhosis receiving glecaprevir/pibrentasvir or sofosbuvir/velpatasvir. Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; SVR12, sustained virologic response 12 weeks after completion of therapy. ^aExtend duration of therapy such that the patient receives the total planned dosage (ie, the total number of daily pills). For example, if a patient missed 10 days of a planned 8-week course of therapy, treatment would be extended to 8 weeks plus 10 days.

within 360 days of diagnosis [24]. A survey conducted among European Association for the Study of the Liver members representing 48 clinical centers also demonstrated decreased HCV testing, diagnosis, and treatment in 2020 compared with 2019 (prepandemic) [25]. Collectively, these findings underscore the critical importance of ongoing, rigorous, universal HCV screening for case identification and linkage to care. In addition, monitoring the proportion of persons who meet steps in the HCV cascade of care will be critical to assessing the quality of HCV care.

Management of Incomplete DAA Adherence

Incomplete medication adherence is well known, even in the highly structured clinical trial setting [26, 27]. Recognizing that incomplete DAA treatment may occur in clinical practice and potentially contribute to treatment failure, the HCV guidance includes a new algorithm for the management of incomplete adherence as part of DAA treatment monitoring (Figure 2). The algorithm is applicable only to DAA treatment-naive persons and, generally, the same patient populations who are eligible for the simplified treatment algorithms described in the following section. Excluded persons with incomplete adherence should be managed in consultation with a specialist in HCV management.

Although few studies have examined incomplete medication adherence in the DAA era, data suggest that it is relatively common, occurring in 11% to 40% of persons on treatment [28–31]. Most episodes of nonadherence appear short-lived. One study demonstrated that 61% of nonadherent episodes lasted 1 to 2 days [31]. These short periods of nonadherence were not associated with virologic failure. Sustained virologic response (SVR) 12 weeks after the completion of treatment (SVR12) was 94% among both adherent and nonadherent participants, where nonadherence was defined as taking <90% of the total prescribed dosage [31]. Longer periods of nonadherence, however, may adversely affect SVR. Investigators who examined the relationship between premature discontinuation of DAA therapy and SVR found that among study participants with F0 to F3 liver disease, SVR12 was 50% in persons who received <4 weeks of DAA treatment compared with 99% SVR12 in those who received ≥4 weeks of treatment [32]. Among participants with compensated cirrhosis, SVR12 rates were 83% and 95% in those who completed <8 weeks of DAA therapy compared with ≥8 weeks of treatment, respectively [32].

Based on these limited findings and the expert consensus of the Guidance Panel, a management algorithm that considers the timing and duration of the nonadherence, as well as specific patient factors (ie, genotype 3 infection and presence of

compensated cirrhosis), is recommended (see Figure 2). Additional large-scale studies in clinical practice settings that examine the relationship between DAA adherence and SVR12, including the threshold level of adherence below which SVR12 is adversely affected, are sorely needed.

INITIAL TREATMENT

Simplified HCV Treatment for Treatment-Naive Adults

The Guidance Panel continues to strongly recommend universal DAA treatment for all people with acute or chronic HCV infection (except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy). A key aspect of facilitating the implementation of this recommendation/goal is expanding the pool of clinicians who provide HCV treatment, thereby boosting accessibility and delivery of care. Accordingly and coincident with the accumulation of real-world data and experience with the pangenotypic DAA regimens, the HCV guidance first introduced the simplified treatment algorithms for treatment-naive persons (without cirrhosis or with compensated cirrhosis) in 2019 [5]. The current update to the simplified treatment algorithms features reduced pretreatment and on-treatment clinician intervention and expanded eligibility of persons who can be treated using these approaches.

Recent data from a global sample of persons undergoing DAA treatment for chronic HCV infection suggest that a minimal on-treatment monitoring approach is safe and effective and leads to an SVR rate that is comparable to that realized with standard monitoring [33]. The minimal monitoring (MINMON) approach was examined in an international, phase 4, open-label,

single-arm trial. Four hundred treatment-naive participants aged ≥ 18 years with active HCV infection were enrolled from 38 sites in Brazil, South Africa, Thailand, Uganda, and the United States. Participants included persons with compensated cirrhosis and HIV coinfection. Key exclusion criteria were pregnancy, breastfeeding, and chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen [HBsAg] positive; due to possible risk of HBV reactivation). However, participants with resolved HBV infection (hepatitis B core antibody [anti-HBc] positive, with or without hepatitis B surface antibodies [anti-HBs]) were eligible. Of the 400 enrolled participants, 399 initiated a planned 12-week course of once-daily sofosbuvir (400 mg)/velpatasvir (100 mg). At entry, 42% (166) were living with HIV, 9% (34) had compensated cirrhosis, and 32% (121 of 374) with an available HBV panel had resolved HBV infection. The 4 components of minimal monitoring included no pretreatment genotyping, dispensing the entire treatment course at entry, no scheduled on-treatment visits or laboratory monitoring, and remote contact at week 4 to assess DAA adherence and at week 22 to schedule SVR assessment at week 24. SVR was achieved by 95% (379 of 399) of those who initiated treatment. Fourteen participants experienced a serious adverse event between treatment initiation and week 28; none were treatment-related or led to treatment discontinuation or death [33].

Given the findings of this minimal monitoring study, treatment-naive persons with HIV/HCV coinfection are newly eligible for a simplified HCV treatment approach. Figure 3 shows the eligibility and exclusion criteria for the simplified HCV treatment approaches. Figure 4 provides an overview of the simplified HCV treatment algorithm for treatment-naive adults without cirrhosis. Figure 5 reviews the simplified treat-




Figure 3. Inclusion and exclusion criteria for simplified HCV treatment algorithm. Abbreviations: eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4 index for liver fibrosis; HCV, hepatitis C virus. ^aNoninvasive serologic tests include HCV FibroSure or enhanced liver fibrosis test. ^bChild-Pugh score based on presence of ascites, hepatic encephalopathy, total bilirubin >2.0 mg/dL, albumin ≤ 3.5 g/dL, or international normalized ratio ≥ 1.7 .




Figure 4. Simplified algorithm for HCV treatment among HCV treatment-naive adults without cirrhosis. Recommended DAA regimens for this simplified treatment approach include either 8 weeks of glecaprevir (300 mg)/pibrentasvir (120 mg) taken with food or 12 weeks of sofosbuvir (400 mg)/velpatasvir (100 mg). More detailed descriptions of the patient evaluation process and antivirals used for HCV treatment can be found on the HCV guidance website. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; DAA, direct-acting antiviral; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4 index for liver fibrosis; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INR, international normalized ratio; SVR, sustained virologic response. ^aFIB-4 is a noninvasive measure of hepatic fibrosis that is calculated by: (age [years] \times AST [U/L]) \div (platelet count [10⁹/L] \times (ALT/2 [U/L])). ^bA patient is presumed to have cirrhosis if they have a FIB-4 score >3.25 or if they have any of the following from a previously performed test: transient elastography indicating cirrhosis (ie, liver stiffness >12.5 kPa), noninvasive serologic test above the proprietary cutoff indicating cirrhosis (eg, FibroSure, enhanced liver fibrosis test), clinical evidence of cirrhosis (eg, liver nodularity and/or splenomegaly on imaging, platelet count $<150\,000/\text{mm}^3$), or prior liver biopsy showing cirrhosis. ^cMedication reconciliation should record currently prescribed medications, over-the-counter drugs, and herbal/dietary supplements. ^dDrug–drug interaction assessment should be performed using the table in the Monitoring Section of the HCV Guidance website or the University of Liverpool drug interaction checker.

ment algorithm for HCV treatment-naive adults with compensated cirrhosis.

The inclusion of persons living with HIV in the simplified HCV treatment algorithm is consistent with the DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV [34]. In this guidance, the decision to expand eligibility to include persons living with HIV was informed by the comparable SVR12 rates in those with and without HIV coinfection in the MINMON study [33], the availability of integrase strand transfer inhibitor–based antiretroviral regimens that mitigate concerns of drug–drug interactions between HIV and HCV medications, and the need to expand treatment access, particularly in the COVID-19 pandemic era.

Initial Treatment Regimens

In the current DAA era of hepatitis C treatment, therapy is safe, effective, of relatively short duration, and curative in most people [1, 17]. Widespread use of recommended initial treatment regimens has the potential to substantially reduce hepatitis C prevalence. Given the many benefits of virologic cure, including reduced risk of cirrhosis, hepatocellular carcinoma, liver-

related mortality [35], and all-cause mortality [35–37], expanded use of DAA treatment and the associated probable cure has the capacity to reduce HCV-related disease burden at individual, national, and potentially global levels.

Since the last published update [5], genotypic activity has been added to the hierarchical ranking of treatment regimens (in addition to recommended or alternative, evidence level, and alphabetical order). Table 1 presents a summary of initial treatment recommendations for treatment-naive adults. Shortening the duration of glecaprevir/pibrentasvir therapy to 8 weeks for persons with compensated cirrhosis is a notable change. The updated recommendation is supported by the findings from the international, single-arm, open-label, phase 3b EXPEDITION-8 trial, titled “Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis” [38]. Investigators enrolled 343 treatment-naive participants aged ≥ 18 years with chronic HCV infection (genotypes 1 through 6) and compensated cirrhosis. Key exclusion criteria included coinfection with HIV and/or HBV or a history of hepatic decompensation. Participants received an 8-week course of once-daily




Figure 5. Simplified algorithm for HCV treatment among HCV treatment-naive adults with compensated cirrhosis. Recommended DAA regimens for this simplified treatment approach include either 8 weeks of glecaprevir (300 mg)/pibrentasvir (120 mg) taken with food for genotypes 1 through 6 or 12 weeks of sofosbuvir (400 mg)/velpatasvir (100 mg) for genotypes 1, 2, 4, 5, or 6. More detailed descriptions of the patient evaluation process and antivirals used for HCV treatment can be found on the HCV Guidance website. Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; DAA, direct-acting antiviral; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INR, international normalized ratio; SVR, sustained virologic response. ^aChild–Pugh score based on presence of ascites, hepatic encephalopathy, total bilirubin >2.0 mg/dL, albumin ≤3.5 g/dL, or INR ≥1.7. Patients with a Child–Pugh score ≥7 (ie, Child–Pugh B or C) have decompensated cirrhosis; this simplified treatment approach is not recommended for patients with decompensated cirrhosis. ^bObtain liver ultrasound within 6 months prior to initiating antiviral treatment to exclude hepatocellular carcinoma and subclinical ascites. This simplified treatment approach is not recommended for patients with hepatocellular carcinoma and/or decompensated cirrhosis. ^cMedication reconciliation should record currently prescribed medications, over-the-counter drugs, and herbal/dietary supplements. ^dDrug–drug interaction assessment should be performed using the table in the Monitoring Section of the HCV Guidance website or the University of Liverpool drug interaction checker. ^eDevelopment of jaundice, ascites, spontaneous bacterial peritonitis, variceal hemorrhage, or hepatic encephalopathy may suggest hepatic decompensation. Patients should be referred to a specialist if they develop worsening liver blood tests (eg, total bilirubin, AST, ALT, INR), jaundice, ascites, encephalopathy, or new liver-related symptoms). ^fUltrasound surveillance for hepatocellular carcinoma (with or without alpha-fetoprotein testing) every 6 months is recommended for patients with cirrhosis, in accordance with AASLD guidance. ^gSee AASLD guidance for recommendations regarding the evaluation and management of varices.

glecaprevir (300 mg)/pibrentasvir (120 mg). SVR12 was 98% (335 of 343) in the intention-to-treat (ITT) population. Seven participants experienced a serious adverse event, only 1 of which was treatment-related. One participant who had low baseline leukocyte and neutrophil counts experienced grade 3 leukopenia and neutropenia that presented on posttreatment day 29, which the investigator considered treatment-related. No adverse event led to treatment discontinuation or death [38].

Another significant change is the recommendation that sofosbuvir/velpatasvir/voxilaprevir may be used as an alternative regimen for persons with genotype 3 infection and compensated cirrhosis. This new recommendation is based on findings from the international, open-label, randomized, phase 3 POLARIS-3 clinical trial, titled “Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase

3 randomized trials” and acknowledges limited access to resistance-associated substitution (RAS) testing in some settings [39]. Investigators enrolled 220 DAA treatment-naive participants with genotype 3 infection and compensated cirrhosis who were randomized to 8 weeks of once-daily sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) or 12 weeks of once-daily sofosbuvir (400 mg)/velpatasvir (100 mg). SVR12 was 96% in both treatment arms [39].

Initial treatment using elbasvir/grazoprevir for genotype 1a infection was changed from a recommended to an alternative regimen because of the need for baseline RAS testing. Additionally, several regimens are no longer recommended because the therapeutics are either no longer available in the United States and/or the regimens have inferior SVR rates compared with currently recommended DAA regimens. These include sofosbuvir and daclatasvir; sofosbuvir and ribavirin;

Table 1. Recommendations for Initial Treatment of Hepatitis C Virus–Infected Adults

| Regimen | Genotype | Classification | Duration | Rating | Caveats and Other Considerations |
|---|---------------------|----------------|----------|-------------------|---|
| Treatment-naïve without cirrhosis or with compensated cirrhosis Glecaprevir/pibrentasvir | 1–6 | Recommended | 8 wk | I, A ^a | |
| Sofosbuvir/velpatasvir | 1–6 | Recommended | 12 wk | I, A ^b | For genotype 3 infection with compensated cirrhosis, NS5A RAS testing is recommended. If baseline NS5A RAS Y93H is present, add weight-based ribavirin or choose another recommended regimen. |
| Ledipasvir/sofosbuvir | 1, 4, 5, 6 | Recommended | 12 wk | I, A ^c | Not recommended for genotype 6e infection if subtype is known. |
| | 1 without cirrhosis | Recommended | 8 wk | I, B | Applicable to patients without cirrhosis who are not living with human immunodeficiency virus and whose HCV RNA is <6 million IU/mL. |
| Elbasvir/grazoprevir | 1b, 4 | Recommended | 12 wk | I, A ^d | |
| | 1a | Alternative | 12 wk | I, A | For genotype 1a infection, NS5A RAS testing is recommended. If baseline RASs are present (ie, substitutions at amino acid positions 28, 30, 31, or 93), another recommended regimen should be used. |
| Sofosbuvir/velpatasvir + weight-based ribavirin | 3 | Alternative | 12 wk | Ila, A | Applicable to genotype 3 infection with compensated cirrhosis and baseline NS5a Y93 RAS. |
| Sofosbuvir/velpatasvir/voxilaprevir | | Alternative | 12 wk | Ila, B | Applicable to genotype 3 infection with compensated cirrhosis and baseline NS5a Y93 RAS. |
| Treatment-naïve with decompensated cirrhosis | | | | | |
| Sofosbuvir/velpatasvir + weight-based ribavirin | 1–6 | Recommended | 12 wk | I, A ^e | Low initial dose of ribavirin (600 mg) is recommended for patients with CTP class C cirrhosis; increase as tolerated. |
| Sofosbuvir/velpatasvir | 1–6 | Recommended | 24 wk | I, A ^e | Applicable to patients who are ribavirin ineligible. |
| Ledipasvir/sofosbuvir + weight-based ribavirin | 1, 4, 5, 6 | Recommended | 12 wk | I, A ^f | Low initial dose of ribavirin (600 mg) is recommended for patients with CTP class C cirrhosis; increase as tolerated. |
| Ledipasvir/sofosbuvir | 1, 4, 5, 6 | Recommended | 24 wk | I, A ^f | Applicable to patients who are ribavirin ineligible. |

Recommendations are listed by recommended vs alternative and by genotypic activity, evidence level, and alphabetically.

Abbreviations: CTP, Child–Turcotte–Pugh score; HCV, hepatitis C virus; NS5A, hepatitis C virus nonstructural protein 5A; RAS, resistance-associated substitution.

^aThe level of evidence rating is I, B for persons with compensated cirrhosis.

^bThe level of evidence rating is I, B for persons with genotype 5 or 6 infection.

^cThe level of evidence rating is Ila, B for persons with genotype 5 or 6 infection and those with genotype 4 infection and compensated cirrhosis.

^dThe level of evidence rating is Ila, B for persons with genotype 4 infection and compensated cirrhosis.

^eOnly available data for genotype 6 infection are in persons with compensated cirrhosis.

^fOnly available data for genotypes 5 or 6 infection are in a small number of persons with compensated cirrhosis.

paritaprevir/ritonavir/ombitasvir/dasabuvir; and sofosbuvir, telaprevir, or boceprevir with pegylated interferon and ribavirin.

RETREATMENT

Although DAA therapy is curative for most persons [1, 17], the small percentage of those in whom treatment fails to result in SVR12 require retreatment. Updated retreatment recommendations focus on DAA treatment failures, specifically, sofosbuvir-based regimen failure; glecaprevir/pibrentasvir failure; and multiple DAA failure, including sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir plus glecaprevir/pibrentasvir (Table 2). Retreatments for sofosbuvir-based or HCV nonstructural protein 5A (NS5A) inhibitor-based treatment failures in persons with decompensated cirrhosis are also noted in Table 2.

Sofosbuvir-based Regimen Failure

Generally, persons who have experienced treatment failure with a sofosbuvir-based regimen should be retreated with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir. The exception is

persons with genotype 3 infection and compensated cirrhosis for whom the addition of weight-based ribavirin to the regimen is recommended. This recommendation is supported by data from clinical trials [40, 41] and real-world cohorts [42–45]. Glecaprevir/pibrentasvir for 16 weeks can be used as an alternative retreatment regimen [46–48]. This regimen, however, has not been evaluated in persons with genotype 3 infection and prior sofosbuvir/NS5A inhibitor exposure and is therefore not recommended for these individuals.

Glecaprevir/Pibrentasvir Failure

For persons with a prior glecaprevir/pibrentasvir treatment failure, retreatment with glecaprevir/pibrentasvir plus ribavirin and sofosbuvir is a recommended retreatment option. This recommendation is supported by findings from the MAGELLAN-3 clinical trial, titled “Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection” [49]. This open-label, phase 3b study evaluated the efficacy and safety of once-daily glecaprevir (300 mg)/pibrentasvir (120 mg) plus sofosbuvir (400 mg) and twice daily weight-based ribavirin for retreatment of persons with a prior

Table 2. Recommendations for Retreatment of Hepatitis C Virus–Infected Adults by Prior Exposure

| Regimen | Genotype | Classification | Duration | Rating | Caveats and Other Considerations |
|---|---------------|----------------|----------|--------------------|--|
| Sofosbuvir-based treatment failure without cirrhosis or with compensated cirrhosis | | | | | |
| Sofosbuvir/velpatasvir/voxilaprevir | 1–6 | Recommended | 12 wk | I, A | For genotype 3 infection with compensated cirrhosis, add weight-based ribavirin if there are no contraindications. |
| Glecaprevir/pibrentasvir | 1, 2, 4, 5, 6 | Alternative | 16 wk | I, A | Not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4A protease inhibitor regimen (eg, elbasvir/grazoprevir). |
| Glecaprevir/pibrentasvir treatment failure without cirrhosis or with compensated cirrhosis | | | | | |
| Glecaprevir/pibrentasvir + sofosbuvir + weight-based ribavirin | 1–6 | Recommended | 16 wk | IIa, B | |
| Sofosbuvir/velpatasvir/voxilaprevir | 1–6 | Recommended | 12 wk | IIa, B | For patients with compensated cirrhosis, addition of weight-based ribavirin is recommended (rating IIa, C). |
| Sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir + glecaprevir/pibrentasvir treatment failure without cirrhosis or with compensated cirrhosis | | | | | |
| Glecaprevir/pibrentasvir + sofosbuvir + weight-based ribavirin | 1–6 | Recommended | 16 wk | IIa, B | Extension to 24 wk should be considered in extremely difficult cases (eg, genotype 3 infection with compensated cirrhosis) or failure following sofosbuvir + glecaprevir/pibrentasvir therapy. |
| Sofosbuvir/velpatasvir/voxilaprevir + weight-based ribavirin | 1–6 | Recommended | 24 wk | IIa, B | |
| Sofosbuvir- or NS5A inhibitor–based treatment failure with decompensated cirrhosis | | | | | |
| Sofosbuvir/velpatasvir + weight-based ribavirin | 1–6 | Recommended | 24 wk | II, C ^a | Low initial dose of ribavirin (600 mg) is recommended for patients with CTP class C cirrhosis; increase as tolerated. |
| Ledipasvir/sofosbuvir + weight-based ribavirin | 1, 4, 5, 6 | Recommended | 24 wk | II, C ^b | Low initial dose of ribavirin (600 mg) is recommended for patients with CTP class C cirrhosis; increase as tolerated. |

Recommendations are listed by recommended vs alternative and by genotypic activity, evidence level, and alphabetically.

Abbreviations: CTP, Child–Turcotte–Pugh score; NS3/4A, hepatitis C virus nonstructural protein 3–4A; NS5A, hepatitis C virus nonstructural protein 5A.

^aOnly available data for genotypes 5 or 6 infection are in a small number of persons with compensated cirrhosis.

^bOnly available data for genotype 6 infection are in persons with compensated cirrhosis.

glecaprevir/pibrentasvir treatment failure. Participants with non–genotype 3 infection without cirrhosis and naive to HCV nonstructural protein 3–4A (NS3/4A) protease inhibitors and NS5A inhibitors received 12 weeks of treatment. Those with genotype 3 infection and/or compensated cirrhosis, and/or prior exposure to NS3/4A protease inhibitors and/or NS5A inhibitors received 16 weeks of treatment. SVR12 was 96% (22 of 23) in the ITT population. One patient experienced a serious adverse event unrelated to treatment. No treatment discontinuations or deaths occurred [49].

Treatment with sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is another recommended option in the setting of prior glecaprevir/pibrentasvir treatment failure. Findings from a prospective, nonrandomized, observational study support this recommendation. Investigators enrolled 31 participants with a history of virologic failure with glecaprevir/pibrentasvir therapy. Participants with compensated cirrhosis were included; those with HBV and/or HIV coinfection were excluded. SVR12 was 94% (29 of 31) with 12 weeks of once-daily sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg). Two participants relapsed at week 4 after completion of therapy. No serious adverse events, treatment discontinuations, or deaths occurred [50]. Although the addition of ribavirin was not evaluated in this study, based on prior studies of DAA failures, addition of weight-based ribavirin to the regimen is recommended for persons with compensated cirrhosis.

Multiple DAA Failures, Including Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir Plus Glecaprevir/Pibrentasvir

The MAGELLAN-3 clinical trial demonstrated the efficacy (96% SVR12; 22 of 23) of glecaprevir/pibrentasvir plus sofosbuvir and weight-based ribavirin for heavily DAA-experienced patients, although no sofosbuvir/velpatasvir/voxilaprevir failures were included [49]. Among patients with a prior sofosbuvir/velpatasvir/voxilaprevir treatment failure, 16 weeks of glecaprevir/pibrentasvir plus sofosbuvir and weight-based ribavirin is recommended based on the improved resistance profile of pibrentasvir and high response rate seen with this duration of therapy among genotype 3–infected participants in the MAGELLAN-3 trial [49]. Extension to 24 weeks or longer with this regimen should be considered for persons with factors that may reduce the likelihood of achieving SVR (eg, genotype 3 infection with cirrhosis or prior treatment failure with glecaprevir/pibrentasvir plus sofosbuvir). While there are case report data that use this treatment duration [51–54], no clinical trial data are available to support such an approach.

A 24-week course of sofosbuvir/velpatasvir/voxilaprevir plus weight-based ribavirin is also recommended for persons with a prior sofosbuvir/velpatasvir/voxilaprevir treatment failure. Although there are currently no published clinical trial data that examine retreatment with sofosbuvir/velpatasvir/voxilaprevir for patients in whom initial therapy with the same regimen failed, a small retrospective, observational study of persons

with an initial DAA treatment failure and a subsequent retreatment failure with sofosbuvir/velpatasvir/voxilaprevir included 4 persons who received 24 weeks of sofosbuvir/velpatasvir/voxilaprevir rescue therapy (1 with the addition of ribavirin). SVR12 was 100% (4 of 4) in this small group of extensively DAA-experienced patients [53]. The recommendation to extend duration of therapy to 24 weeks in conjunction with weight-based ribavirin when retreating with the same DAA regimen (sofosbuvir/velpatasvir/voxilaprevir) is predominantly based on extrapolation from prior studies that have shown benefit with this strategy in different populations [55].

Retreatment in Patients With Decompensated Cirrhosis

Retreatment of persons with decompensated cirrhosis and a history of DAA-based treatment failure is limited by the inability to use an NS3/4A protease inhibitor (eg, glecaprevir, grazoprevir, voxilaprevir) in the setting of decompensated cirrhosis. Recommendations to retreat with a 24-week course of either sofosbuvir/velpatasvir plus weight-based ribavirin or ledipasvir/sofosbuvir plus weight-based ribavirin are based on the relatively favorable SVR rates (91% to 100%) with these regimens among patients with compensated cirrhosis and prior DAA failure [55–57].

MANAGEMENT OF UNIQUE AND KEY POPULATIONS

The HCV guidance stresses the importance of addressing the special considerations and unmet needs of unique and key populations to achieve significant reductions in the burden of HCV-related disease. This approach aligns with the WHO strategy for achieving hepatitis C elimination targets, which also emphasizes the importance of focusing efforts on populations disproportionately affected by HCV infection, specifically HIV/HCV-coinfected persons, people who inject drugs (PWID), men who have sex with men (MSM), and incarcerated persons [1]. The HCV guidance additionally focuses on the special considerations and unmet needs of other unique or key populations, namely, individuals with acute HCV infection, pregnant persons, children and adolescents, and solid organ transplant recipients. Recommendations for these populations aim to maximize the potential benefits of often missed opportunities to reduce hepatitis C infection incidence and prevalence, personal and societal disease burden, and HCV-related morbidity and mortality.

HIV/HCV Coinfection

Treatment-naïve persons living with HIV and HCV (without cirrhosis or with compensated cirrhosis) are newly eligible for DAA therapy using a simplified treatment algorithm (see Figures 4 and 5). This recommendation is supported by findings from the MINMON clinical trial, titled “A minimal monitoring approach for the treatment of hepatitis C virus infection

(ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial”. Among the 166 study participants living with HIV and HCV, 95% (157 of 166) achieved SVR12 [33]. Given that people living with HIV are disproportionately affected by HCV infection [58], the reduction in treatment barriers benefits the affected individuals while furthering the goal of HCV elimination.

Acute HCV Infection

The Guidance Panel reiterates the recommendation that persons with confirmed acute HCV infection (HCV RNA-positive) should be treated the same as those with chronic HCV infection without awaiting possible spontaneous clearance (ie, a test-and-treat approach). Given that the incidence of acute hepatitis C in the United States increased 124% from 2013 through 2020 [59], treatment of this key population is critical to both HCV prevention and elimination.

Findings from studies that evaluated the efficacy of an abbreviated 6 weeks of therapy for acute HCV infection with various DAA regimens, including ledipasvir/sofosbuvir [60, 61], glecaprevir/pibrentasvir [62], and sofosbuvir/velpatasvir [63], have demonstrated largely inferior response rates compared with the standard of care. As such, an abbreviated course of DAA therapy is not recommended for acute HCV infection.

HCV in Pregnancy

Following the 2018 HCV guidance recommendation for universal hepatitis C screening during pregnancy [64], the USPSTF and CDC issued largely concurrent recommendations in 2020 [8, 9]. In May 2021, the American College of Obstetricians and Gynecologists issued a practice advisory recommending hepatitis screening for all pregnant persons during each pregnancy [65]. The Society for Maternal-Fetal Medicine endorsed that practice advisory and published a concurring recommendation in September 2021 [66]. Given that the DHHS viral hepatitis national strategic plan specifies expanded implementation of universal hepatitis C screening during pregnancy as an important strategy for actualizing HCV elimination [4], the coalescence of screening recommendations for this key population is an important step toward achieving that goal. Treatment recommendations during pregnancy are largely unchanged from the previous update [5]. Although there have been no published large-scale clinical trials to evaluate the safety of DAA therapy during pregnancy, smaller studies and case series have not demonstrated any safety concerns [67–71]. The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits.

HCV in Children

Strategies to reduce the burden of HCV-related disease have historically focused on the adult population [72]. Data from a

recent modeling study indicate that at least 3.26 million children and adolescents (aged ≤ 18 years) are living with HCV infection worldwide [73]. National hepatitis C incidence and prevalence data among children and adolescents in the United States are sparse and/or outdated [73]. However, with the recent increase in HCV infection among women of child-bearing age [15, 74–78] comes a coincident risk of increased cases of mother-to-child transmission [76], the primary route of HCV transmission in children [79, 80].

Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 [81, 82] to the June 2021 approval of 2 pan-genotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years [83, 84]. Efficacy and safety data from therapeutic DAA clinical trials conducted in children are largely comparable to those from studies conducted in adults [85–90]. As such, the Guidance Panel reaffirms its recommendation to treat all HCV-infected children and adolescents aged ≥ 3 years with an approved DAA regimen regardless of disease severity. Treatment and retreatment recommendations for children are shown in Tables 3 and 4, respectively.

Table 3. Recommendations for Initial Treatment of Hepatitis C Virus-Infected Pediatric Patients Without Cirrhosis or With Compensated Cirrhosis

| Regimen | Genotype | Classification | Duration | Rating |
|--------------------------|------------|----------------|----------|--------|
| Glecaprevir/pibrentasvir | 1–6 | Recommended | 8 wk | I, B |
| Sofosbuvir/velpatasvir | 1–6 | Recommended | 12 wk | I, B |
| Ledipasvir/sofosbuvir | 1, 4, 5, 6 | Recommended | 12 wk | I, B |

Recommendations are listed by genotypic activity, evidence level, and alphabetically.

Table 4. Recommendations for Retreatment of Hepatitis C Virus-Infected Pediatric Patients by Prior Exposure and Cirrhosis Status

| Regimen | Genotypes | Classification | Duration | Rating | Cirrhosis Status |
|--|---------------|----------------|----------|--------|---|
| Interferon-based regimen (\pm ribavirin) and/or sofosbuvir treatment failure without NS3/4A protease inhibitor or NS5A inhibitor exposure | | | | | |
| Glecaprevir/pibrentasvir | 1, 2, 4, 5, 6 | Recommended | 8 wk | I, C | No cirrhosis |
| Glecaprevir/pibrentasvir | 1, 2, 4, 5, 6 | Recommended | 12 wk | I, C | Compensated cirrhosis |
| Glecaprevir/pibrentasvir | 3 | Recommended | 16 wk | I, C | Without cirrhosis or with compensated cirrhosis |
| Sofosbuvir/velpatasvir | 1–6 | Recommended | 12 wk | I, C | Without cirrhosis or with compensated cirrhosis |
| Sofosbuvir/velpatasvir + weight-based ribavirin | 1–6 | Recommended | 12 wk | I, C | Decompensated cirrhosis |
| NS3/4A protease inhibitor treatment failure without NS5A inhibitor exposure | | | | | |
| Glecaprevir/pibrentasvir | 1–6 | Recommended | 12 wk | I, C | Without cirrhosis or with compensated cirrhosis |
| NS5A inhibitor treatment failure without NS3/4A protease inhibitor exposure | | | | | |
| Glecaprevir/pibrentasvir | 1–6 | Recommended | 16 wk | I, C | Without cirrhosis or with compensated cirrhosis |
| Interferon (\pm ribavirin) plus a hepatitis C virus protease inhibitor treatment failure | | | | | |
| Ledipasvir/sofosbuvir | 4, 5, 6 | Recommended | 12 wk | I, C | Without cirrhosis or with compensated cirrhosis |
| Ledipasvir/sofosbuvir | 1 | Recommended | 12 wk | I, C | No cirrhosis |
| Ledipasvir/sofosbuvir | 1 | Recommended | 24 wk | I, C | Compensated cirrhosis |

Recommendations are listed by genotypic activity, evidence level, and alphabetically.

Abbreviations: NS3/4A, hepatitis C virus nonstructural protein 3–4A; NS5A, hepatitis C virus nonstructural protein 5A.

Management of HCV After Solid Organ Transplantation

Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation [91–95]. Discussion of specific clinical scenarios follows. Table 5 shows HCV treatment recommendations posttransplantation.

Treatment of Recurrent HCV Infection Post Liver and Kidney Transplantation

The phase 3, single-arm, open-label MAGELLAN-2 trial, titled “Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection” evaluated a 12-week course of once-daily glecaprevir (300 mg)/pibrentasvir (120 mg) for the treatment of HCV infection (genotypes 1 through 6) among patients without cirrhosis who had undergone liver or kidney transplantation and were ≥ 3 months posttransplantation. Those whose immunosuppressive regimen included cyclosporine > 100 mg/d or prednisone > 10 mg/d were excluded. Treatment-naive and treatment-experienced (genotypes 1, 2, 4, 5, 6; prior treatment with interferon-based therapy or sofosbuvir plus ribavirin with or without pegylated interferon) participants were included. Treatment-experienced persons with genotype 3 infection were excluded. Overall, SVR12 was 98% (98 of 100). No treatment-related serious adverse events were reported [91].

Sofosbuvir-based regimens have also shown efficacy in persons who have undergone liver or kidney transplantation [93–96]. Investigators who conducted a real-world observational study to evaluate the efficacy and safety of DAA therapy in 179 liver, kidney, or dual liver and kidney transplant recipients reported an SVR12 of 94% (169 of 179) among participants treated with ledipasvir/sofosbuvir. Adverse events, including acute cellular rejection, were rare [93]. A phase 2, open-label study that evaluated 12 weeks of daily sofosbuvir (400 mg)/velpatasvir (100 mg) in 79 HCV-infected (genotypes 1, 2, 3, 4)

Table 5. Recommendations for Hepatitis C Virus Treatment Posttransplantation

| Regimen | Genotypes | Classification | Duration | Rating | Caveats and Other Considerations |
|---|------------|----------------|-------------------|--|--|
| Recurrent HCV post liver transplant without cirrhosis | | | | | |
| Glecaprevir/ pibrentasvir | 1–6 | Recommended | 12 wk | I, B | |
| Sofosbuvir/ velpatasvir | 1–6 | Recommended | 12 wk | I, B | |
| Ledipasvir/ sofosbuvir | 1, 4, 5, 6 | Recommended | 12 wk | I, B | |
| Recurrent HCV post liver transplant with compensated cirrhosis | | | | | |
| Sofosbuvir/ velpatasvir | 1–6 | Recommended | 12 wk | I, B | |
| Glecaprevir/ pibrentasvir | 1–6 | Recommended | 12 wk | I, C | |
| Ledipasvir/ sofosbuvir | 1, 4, 5, 6 | Recommended | 12 wk | I, A | |
| Recurrent HCV post kidney transplant without cirrhosis or with compensated cirrhosis | | | | | |
| Glecaprevir/ pibrentasvir | 1–6 | Recommended | 12 wk | I, A ^a IIa, C ^b | |
| Sofosbuvir/ velpatasvir | 1–6 | Recommended | 12 wk | IIa, C | |
| Ledipasvir/ sofosbuvir | 1, 4, 5, 6 | Recommended | 12 wk | I, A | |
| Elbasvir/ grazoprevir | 1, 4 | Alternative | 12 wk | I, B | Limited to patients without baseline NS5A RASs for elbasvir. |
| HCV-uninfected recipients of liver grafts from HCV-viremic donors | | | | | |
| Glecaprevir/ pibrentasvir | 1–6 | Recommended | 12 wk | I, C | Timing: initiate treatment within the first 2 wk posttransplant, preferably within the first week. |
| Sofosbuvir/ velpatasvir | 1–6 | Recommended | 12 wk | I, C | Timing: initiate treatment within the first 2 wk posttransplant, preferably within the first week. |
| HCV-uninfected recipients of non-liver solid organs from HCV-viremic donors | | | | | |
| Glecaprevir/ pibrentasvir | 1–6 | Recommended | 8 wk ^c | I, C | Timing: initiate treatment prior to HCV RNA results, immediately pretransplant or day 0 posttransplant, if possible. Otherwise, begin on day 0 to within the first week posttransplant when clinically stable. |
| Sofosbuvir/ velpatasvir | 1–6 | Recommended | 12 wk | I, C | Timing: initiate treatment prior to HCV RNA results, immediately pretransplant or day 0 posttransplant, if possible. Otherwise, begin on day 0 to within the first week posttransplant when clinically stable. |

Recommendations are listed by genotypic activity, evidence level, and alphabetically.

Abbreviations: HCV, hepatitis C virus; NS5A, hepatitis C virus nonstructural protein 5A; RAS, resistance associated substitution.

^aRating is based on evidence for persons without cirrhosis.

^bRating is based on evidence for persons with compensated cirrhosis.

^cIf treatment initiation is delayed beyond the first week after transplant, treatment should be extended to 12 weeks.

liver transplant recipients demonstrated a similar response rate with an SVR12 of 96% (76 of 79). No treatment-related serious adverse events, transplant rejection episodes, or deaths occurred during the study period [94].

Important drug–drug interactions unique to the posttransplant setting should be addressed prior to initiation of DAA therapy. Cyclosporine significantly increases the area under the curve of elbasvir/grazoprevir [97, 98] as well as sofosbuvir/velpatasvir/voxilaprevir [99] and should not be coadministered with these regimens. Coadministration of glecaprevir/pibrentasvir and cyclosporine >100 mg/d is also not recommended [83].

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

A large disparity persists among people in need of solid organ transplantation and available deceased donor organs [100].

Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs [101–106]. The pool of HCV-positive donors includes both HCV-viremic donors (ie, HCV RNA-positive) and HCV-seropositive donors (ie, HCV antibody-positive, HCV RNA-negative [nonviremic]). The use of HCV-positive organs has been shown to be an effective strategy for increasing access to transplantation and reducing wait-list time and overall mortality [107–110].

Timing and Treatment of HCV-Viremic Liver Grafts in Nonviremic Recipients. Emerging data support HCV treatment as early as possible when transplanting an HCV-viremic liver graft into an HCV-seronegative recipient [111]. In a recent multicenter

prospective study, 34 HCV-seronegative liver transplant patients underwent transplantation using organs from HCV-positive donors (20 viremic, 14 nonviremic). All recipients of grafts from HCV-viremic donors became viremic by day 3 posttransplantation. DAA treatment was initiated in these graft recipients a median of 27.5 days after transplantation. SVR12 was 100% (20 of 20). One patient developed acute HCV-related membranous nephropathy on postoperative day 18 (prior to initiation of DAA therapy), ultimately resulting in end-stage renal disease requiring dialysis despite achieving SVR12 [112]. This case highlights the importance of early initiation of DAA therapy posttransplantation to avoid HCV-related complications. The Guidance Panel recommends initiating therapy at least within 2 weeks after transplantation but preferably within 1 week when the patient is clinically stable.

An abbreviated duration of DAA therapy is currently not recommended for recipients of organs from HCV-viremic donors due to lack of data demonstrating efficacy. The large reservoir of HCV in a transplanted liver graft may be responsible for the lack of efficacy.

Timing and Treatment of HCV-Viremic Non-Liver Grafts in Nonviremic Recipients. HCV treatment should occur as early as possible in HCV-seronegative patients who undergo transplantation with a non-liver graft from an HCV-viremic donor. This strategy reduces the likelihood of hepatic and extrahepatic HCV-related complications in the immediate posttransplant period. The phase 4, open-label, multicenter MYTHIC clinical trial evaluated the efficacy and safety of 8 weeks of once-daily glecaprevir (300 mg)/pibrentasvir (120 mg) in 30 HCV-negative kidney transplant recipients who underwent transplantation using a graft from an HCV-viremic donor [113]. Treatment initiation occurred 2 days to 5 days posttransplantation (target was 3 days). All 30 participants achieved SVR12; no HCV-related serious adverse events were reported [113]. Based on this study and others showing benefit(s) associated with early HCV treatment [113–116], use of a prophylactic (immediately prior to transplantation or day 0 posttransplantation) or preemptive (day 0 to day 7 posttransplantation; as soon as the patient is clinically stable) strategy for initiation of DAA treatment is recommended for HCV-negative recipients of a non-liver solid organ graft from an HCV-viremic donor. Note that neither approach requires demonstration of HCV viremia in the transplant recipient.

Shorter durations of DAA-based therapy in this setting are currently under investigation with promising results. These practices, however, are currently not recommended outside of a clinical trial [115, 117, 118].

Outcomes and Process in Transplantation Using HCV-Viremic Donor Grafts in HCV-Seronegative Recipients. Data evaluating longer-

term patient outcomes after transplantation with an HCV-viremic donor organ have shown encouraging results. Among 51 dual heart/kidney transplant recipients undergoing transplantation with organs from HCV-viremic donors, 1-year survival was comparable to survival in those who received organs from nonviremic donors [119]. Another study that evaluated outcomes among multiorgan transplant recipients (heart/kidney, heart/lung, heart/liver) demonstrated similar 1-year survival among recipients of organs from HCV-viremic donors compared with those who received organs from HCV-negative donors [106].

In an analysis of the United Network for Organ Sharing database, HCV-negative liver transplant patients who received the graft from an HCV-positive donor (viremic and nonviremic) were shown to have superior 1-year graft survival rates compared with those who received a graft from an HCV-negative donor [120]. Notably, HCV-positive donors were statistically significantly younger than their HCV-negative counterparts. Multivariate analysis demonstrated that donor age, but not donor HCV status, was an independent predictor of 1-year graft survival [120].

Extensive informed consent, as recommended by the American Society of Transplantation Consensus Panel [121], and shared decision-making between the patient and clinical team should occur prior to transplantation of an HCV-viremic organ into an HCV-negative recipient. Patients should understand the risk of HCV infection, risk to caregivers from needlestick exposures, as well as success rates and risks of DAA-based therapy [115, 121–125]. Given the breadth of safety and efficacy data now available, institutional review board–approved protocols are no longer required. However, based on the unique factors noted, transplant centers should have a specific HCV consent and follow-up process in place.

People Who Inject Drugs

Injection drug use (IDU) is the most common risk factor for HCV infection in North America and Europe. The HCV seroprevalence among PWID ranges from 18% to 88%, depending on geographic location [126] and duration of IDU exposure [127, 128]. IDU accounts for approximately 70% of new HCV infections [59]. Thus, the growing opioid epidemic has become an important force in the perpetuation of the HCV epidemic [1, 2, 4, 14, 16, 59]. Consequently, achieving the goal of HCV elimination depends heavily on diagnosing and treating HCV infection in PWID and on implementing harm reduction strategies to prevent future infections [1, 2, 4, 122, 129–132]. Data from Australia support the efficacy of the treatment-as-prevention approach among PWID. After implementation of unrestricted access to DAA therapy in 2016, the proportion of PWID diagnosed with active HCV infection who were treated increased from 3% to 47%, while the

proportion of those with HCV viremia declined from 44% to 17% [133].

Annual HCV testing is recommended for PWID with ongoing IDU regardless of either no prior testing or past negative testing. Substance use disorder treatment programs and needle/syringe exchange programs should offer routine, opt-out HCV antibody testing with confirmatory HCV RNA testing and linkage to care for those determined to be HCV-infected [132, 134]. PWID with HCV infection should be counseled about measures to reduce the risk of transmission to others and offered linkage to harm reduction services, including intranasal naloxone, needle/syringe service programs, medications for opioid use disorder, and other substance use disorder treatment programs.

Clinical trials and observational studies of PWID reporting current IDU at the start of HCV treatment and/or continued use during therapy demonstrate SVR12 rates approaching 95% [135–140]. The Guidance Panel strongly asserts that active or recent drug use or concern for reinfection is not a contraindication to HCV treatment. At least annual HCV RNA testing is recommended for PWID with recent IDU after they have spontaneously cleared HCV infection or have been successfully treated [141–144].

Men Who Have Sex With Men Not Living With HIV

While the increased risk of HCV infection among MSM living with HIV is well known [145], acute HCV infections have also been reported among MSM not living with HIV who present for HIV preexposure prophylaxis (PrEP) [146, 147]. HCV testing at HIV PrEP initiation and at least annually thereafter (while on PrEP) is recommended for MSM not living with HIV. All MSM should be counseled about the risk of sexual HCV transmission with high-risk sexual and drug use practices and educated about measures to prevent HCV infection or transmission [148, 149].

Antiviral treatment for HCV-infected MSM should be coupled with ongoing counseling about the risk of HCV reinfection and education about methods to reduce HCV reinfection risk after cure [150]. At least annual (and risk-based, if indicated) HCV RNA testing is recommended for all high-risk sexually active MSM after successful treatment or spontaneous clearance of HCV infection [151, 152].

Persons in Correctional Settings

Recent cross-sectional surveys suggest that the HCV seroprevalence among incarcerated populations in the United States ranges from 3.0% to 34.6% [153], which exceeds the 1.7% HCV seroprevalence in the general population [154]. More than 90% of these persons are eventually released and reenter the general population where they can contribute to HCV spread in the community [155, 156] and may have little contact with the healthcare system [157, 158]. Given the high HCV

prevalence among persons in the US correctional system, the success of the US HCV elimination effort depends on identifying infected individuals in jails and prisons, linking these persons to medical care for HCV management, and providing access to antiviral treatment [2, 159]. Jails and prisons should therefore implement opt-out HCV testing that consists of HCV antibody testing followed by confirmatory HCV RNA testing if antibody-positive. Universal opt-out testing of incarcerated persons for chronic HCV is highly cost-effective and has been shown to reduce ongoing HCV transmission and the incidence of advanced liver disease [160].

DAA treatment for chronic HCV infection is feasible within jail and prison settings and would aid the HCV elimination effort [161, 162]. Chronically infected persons residing in jails should receive counseling about HCV infection and be provided linkage to follow-up community healthcare for evaluation of liver disease and treatment upon release [163–166]. Those whose jail sentence is sufficiently long to complete a recommended course of DAA therapy should receive that treatment while incarcerated [161]. Chronically infected individuals in prison should receive DAA therapy according to AASLD–IDSA guidance while incarcerated [162, 167]. Jails and prisons should facilitate continuation of HCV therapy for persons on HCV treatment at the time of incarceration. HCV treatment in correctional settings is cost-effective because DAAs halt progression of HCV-related liver disease and decrease the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma, offsetting future healthcare costs from liver and non-liver complications [168].

Upon release from a correctional facility, HCV-infected persons with advanced hepatic fibrosis or cirrhosis should be provided linkage to community healthcare for surveillance for HCV-related complications. To prevent HCV reinfection and reduce the risk of progression of HCV-associated liver disease, correctional facilities should provide harm reduction and evidence-based treatment for underlying substance use disorders [169]. Addressing hazardous alcohol use among persons with chronic HCV in a correctional setting may help slow liver disease progression, decrease HCV transmission, and might reduce recidivism.

Notes

Acknowledgments. The panel thanks the able staff of the Infectious Diseases Society of America (IDSA) and the American Association for the Study of Liver Diseases (AASLD), particularly Jon Heald, Genet Demisashi, Elizabeth Durzy, Audrey Davis-Owino, and Sheila Tynes for project management and administrative support of the Hepatitis C Virus (HCV) Guidance Project, and Dr Tina M. St. John for technical and editorial support of the HCV Guidance Project and manuscript preparation assistance.

Disclaimer. This article does not necessarily represent the views and policies of the US Preventive Services Task Force.

Financial support. The work for the HCV Guidance Project is supported exclusively by the AASLD and the IDSA.

AASLD–IDSA HCV Guidance Panel members and authors.

Co-Chairs

Andrew I. Aronsohn, MD, Department of Medicine, Section of Gastroenterology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA; Debika Bhattacharya, MD, Department of Medicine, Division of Infectious Diseases, University of California–Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; Vincent Lo Re, MD, MSCE, Department of Medicine, Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; and Jennifer C. Price, MD, PhD, Department of Medicine, Division of Gastroenterology, University of California–San Francisco School of Medicine, San Francisco, CA, USA

Panel Members

Jordan J. Feld, MD, MPH, University of Toronto, Toronto, ON, Canada; Stuart C. Gordon, MD, Henry Ford Health System, Division of Hepatology, Detroit, MI, USA; Theo Heller, MD, National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Bethesda, MD, USA; Ravi Jhaveri, MD, FIDSA, FPIDS, FAAP, Department of Pediatrics, Division of Pediatric Infectious Diseases, Feinberg Northwestern School of Medicine, Chicago, IL, USA; Maureen M. Jonas, MD, Division of Gastroenterology, Children's Hospital of Boston, Harvard Medical School, Boston, MA, USA; Jennifer J. Kiser, PharmD, PhD, Center for Translational Pharmacokinetics and Pharmacogenomics, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; Benjamin P. Linas, MD, MPH, Department of Medicine, Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA; Timothy R. Morgan, MD, Department of Medicine, Veterans Affairs Long Beach Healthcare System, Long Beach, CA, USA, and University of California Irvine School of Medicine, Orange, CA, USA; K. Rajender Reddy, MD, Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA;

Andrew Reynolds, Hepatitis C Wellness Manager, San Francisco AIDS Foundation, San Francisco, CA, USA; John D. Scott, MD, MSc, FIDSA, Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA, USA; Gloria Searson, ACSW, Founding Director and Executive Director, Coalition on Positive Health Empowerment, New York, NY, USA; Philip Spradling, MD, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, US Centers for Disease Control and Prevention, Atlanta, GA, USA; Norah A. Terrault, MD, Department of Medicine, Division of Gastroenterology and Liver Diseases, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA; Elizabeth C. Verna, MD, MS, Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; John B. Wong, MD, Department of Medicine, Division of Clinical Decision Making, Tufts University School of Medicine, Boston, MA, USA;

Ann E. Woolley, MD, MPH, Department of Medicine, Division of Infectious Diseases, Harvard Medical School, Boston, MA, USA; Kimberley A. Workowski, MD, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; and David L. Wyles, MD, Department of Medicine, Division of Infectious Diseases, Denver Health, University of Colorado School of Medicine, Denver, CO, USA.

Potential conflicts of interest. D. B. reports research grants, paid to institution, from Gilead Sciences, Inc. J. C. P. reports research grants, paid to institution, from Gilead Sciences, Inc and Merck & Co, Inc (spouse has interest in stock that is independently managed in AbbVie, Inc, Bristol Myers Squibb Co, Johnson & Johnson, and Merck & Co, Inc). J. J. F. reports serving as a scientific consultant to AbbVie, Inc, Bluejay Therapeutics, Inc, Deep Genomics, Inc, Gilead Sciences, Inc, GSK Plc, and Janssen Pharmaceutical Companies of Johnson & Johnson and grants, paid to institution, from AbbVie, Inc, Alexion AstraZeneca Rare Disease, Altimmune, Inc, Eiger Biopharmaceuticals, Inc, Enanta Pharmaceuticals, Inc, Gilead Sciences, Inc, GSK Plc, Janssen Pharmaceutical Companies of Johnson &

Johnson, and Fujifilm Wako Chemicals Corp. S. C. G. reports research grants, paid to institution, from AbbVie, Inc, Gilead Sciences, Inc, and Merck & Co, Inc. R. J. reports participation on the AstraZeneca/Sanofi Advisory Board, being an expert panel member for Moderna, being an advisory board member/consultant for Seqirus, being a consultant for AstraZeneca and Dynavax, royalties from UpToDate, an editorial stipend from PIDS, and a research grant from GSK Plc. M. M. J. reports serving as a scientific consultant to Gilead Sciences, Inc and research grants, paid to institution, from AbbVie, Inc, Gilead Sciences, Inc, F. Hoffmann-La Roche AG, and Merck & Co, Inc. J. J. K. reports research grants, paid to institution, from Gilead Sciences, Inc. T. R. M. reports research grants, paid to institution, from AbbVie, Inc, Genfit, Gilead Sciences, Inc, and Merck & Co, Inc. K. R. R. reports serving on scientific advisory boards for Spark Therapeutics, Novo Nordisk, Genfit, BioVie, and Mallinckrodt; serving on a data and safety monitoring board (DSMB) for Novartis and AstraZeneca; grants, paid to institution, from Bristol Myers Squibb Co, Exact Sciences Corp, Grifols, Intercept Pharmaceuticals, Inc, BioVie, Mallinckrodt Pharmaceuticals, Merck & Co, Inc, Sequana Medical Co, HCC-TARGET, and NASH-TARGET. A. R.'s organization was awarded educational grants from AbbVie, Inc and Gilead Sciences, Inc. J. D. S. reports personal financial relationships with Gilead Sciences, Inc and Premera Blue Cross. G. S.'s organization was awarded grants from AbbVie, Inc, Gilead Sciences, Inc, and Merck & Co, Inc. N. A. T. reports serving on the DSMB of Moderna, Inc and research grants, paid to institution, from Gilead Sciences, Inc, GSK Plc, Helio Health Group, and F. Hoffmann-La Roche AG (Genentech). E. C. V. reports serving on an advisory board for Gilead Sciences, Inc and research grants, paid to institution, from Salix Pharmaceuticals, Inc. J. B. W. is a member of the US Preventive Services Task Force. K. W. reports research grants, paid to institution, from Gilead Sciences, Inc. D. L. W. reports research grants, paid to institution, from Gilead Sciences, Inc. J. P. reports grant support, paid to institution, from AbbVie, Inc, Zydus, and Genentech. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. Published June 2016. Available at: <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf>. Accessed 28 November 2022.
2. National Academies of Sciences, Engineering, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. Washington, DC: National Academies Press, 2017.
3. US Centers for Disease Control and Prevention. Healthy people 2030, infectious disease. Available at: <https://health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease>. Accessed 21 November 2022.
4. US Department of Health and Human Services. Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021–2025). Published 7 January 2021. Available at: <https://www.hhs.gov/hepatitis/viral-hepatitis-national-strategic-plan/index.html>. Accessed 25 November 2022.
5. Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology* 2020; 71:686–721.
6. American Heart Association. Methodology manual and policies from the ACCF/AHA Task Force on Practice Guidelines. Dallas, TX: American College of Cardiology Foundation and American Heart Association, Inc, 2010.
7. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. *Ann Intern Med* 2003; 139:493–8.
8. Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *JAMA* 2020; 323:970–5.
9. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. *MMWR Recomm Rep* 2020; 69:1–17.
10. Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens. *Clin Gastroenterol Hepatol* 2019; 17:930–939.e9.

11. Buti M, Domínguez-Hernández R, Casado MA, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. *PLoS One* **2018**; 13:e0208036.
12. Wong WWL, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. *CMAJ* **2015**; 187:E110–21.
13. Barocas JA, Tasillo A, Eftekhari Yazdi G, et al. Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States. *Clin Infect Dis* **2018**; 67:549–56.
14. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. *MMWR Morb Mortal Wkly Rep* **2015**; 64:453–8.
15. Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. *Ann Intern Med* **2017**; 166:775–82.
16. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. *Clin Infect Dis* **2014**; 59:1411–9.
17. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. *Ann Intern Med* **2017**; 166:637–48.
18. Ferrante ND, Newcomb CW, Forde KA, et al. The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially insured population. *Open Forum Infect Dis* **2022**; 9:ofac445.
19. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. *PLoS One* **2014**; 9:e101554.
20. Yeo YH, Gao X, Wang J, et al. The impact of COVID-19 on the cascade of care of HCV in the US and China. *Ann Hepatol* **2022**; 27:100685.
21. Kaufman HW, Bull-Otterson L, Meyer WA 3rd, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. *Am J Prev Med* **2021**; 61:369–76.
22. US Centers for Disease Control and Prevention. CDC museum COVID-19 timeline. Last reviewed 16 August 2022. Available at: <https://www.cdc.gov/museum/timeline/covid19.html>. Accessed 29 November 2022.
23. Mandel E, Peci A, Cronin K, et al. The impact of the first, second and third waves of COVID-19 on hepatitis B and C testing in Ontario, Canada. *J Viral Hepat* **2022**; 29:205–8.
24. Thompson WW, Symum H, Sandul A, et al. Vital signs: hepatitis C treatment among insured adults—United States, 2019–2020. *MMWR Morb Mortal Wkly Rep* **2022**; 71:1011–7.
25. Kondili LA, Buti M, Riveiro-Barciela M, et al. Impact of the COVID-19 pandemic on hepatitis B and C elimination: an EASL survey. *JHEP Rep* **2022**; 4:100531.
26. Breckenridge A, Aronson JK, Blaschke TF, Hartman D, Peck CC, Vrijens B. Poor medication adherence in clinical trials: consequences and solutions. *Nat Rev Drug Discov* **2017**; 16:149–50.
27. Nieuwlaar R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev* **2014**; 2014:CD000011.
28. Serper M, Evon DM, Stewart PW, et al. Medication non-adherence in a prospective, multi-center cohort treated with hepatitis C direct-acting antivirals. *J Gen Intern Med* **2020**; 35:1011–20.
29. Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. *Ann Intern Med* **2019**; 170:594–603.
30. Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. *Clin Infect Dis* **2020**; 71:e115–e24.
31. Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. *Int J Drug Policy* **2018**; 62:14–23.
32. Fabbiani M, Lombardi A, Colaneri M, et al. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. *J Viral Hepat* **2021**; 28:558–68.
33. Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. *Lancet Gastroenterol Hepatol* **2022**; 7:307–17.
34. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Disease Society of America, **2023**. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection>.
35. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *Lancet* **2019**; 393:1453–64.
36. Kalidindi Y, Jung J, Feldman R, Riley T 3rd. Association of direct-acting antiviral treatment with mortality among Medicare beneficiaries with hepatitis C. *JAMA Netw Open* **2020**; 3:e2011055.
37. Chou R, Dana T, Fu R, et al. Screening for hepatitis C virus infection in adolescents and adults: a systematic review update for the U.S. Preventive Services Task Force [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US), **2020**.
38. Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial. *J Hepatol* **2020**; 72:441–9.
39. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. *Gastroenterology* **2017**; 153:113–22.
40. Bourlière M, Gordon SC, Schiff ER, et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. *Lancet Gastroenterol Hepatol* **2018**; 3:559–65.
41. Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. *N Engl J Med* **2017**; 376:2134–46.
42. Da BL, Lourdasamy V, Kushner T, Dieterich D, Saberi B. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. *Eur J Gastroenterol Hepatol* **2021**; 33:859–61.
43. Belperio PS, Shahoumian TA, Loomis TP, Backus LI. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. *J Viral Hepat* **2019**; 26:980–90.
44. Degasperis E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. *J Hepatol* **2019**; 71:1106–15.
45. Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. *J Hepatol* **2019**; 71:666–72.
46. Poordad F, Pol S, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. *Hepatology* **2018**; 67:1253–60.
47. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. *Hepatology* **2017**; 66:389–97.
48. Lok AS, Sulkowski MS, Kort JJ, et al. Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy. *Gastroenterology* **2019**; 157:1506–17.e1.
49. Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. *J Hepatol* **2019**; 70:1019–23.
50. Pearlman B, Perrys M, Hinds A. Sofosbuvir/velpatasvir/voxilaprevir for previous treatment failures with glecaprevir/pibrentasvir in chronic hepatitis C infection. *Am J Gastroenterol* **2019**; 114:1550–2.
51. Bernhard B, Stickle F. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. *Z Gastroenterol* **2020**; 58:451–5.
52. Fierer DS, Wyles DL. Re-treatment of hepatitis C infection after multiple failures of direct-acting antiviral therapy. *Open Forum Infect Dis* **2020**; 7:ofaa095.
53. Dietz J, Di Maio VC, de Salazar A, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. *J Hepatol* **2021**; 74:801–10.
54. Trudeau S, Mendiratta V, Dababneh Y, Hollingsworth J, Gordon SC. Letter to the editor: successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals. *Hepatology* **2023**; 77:E9–E10.
55. Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. *Hepatology* **2017**; 66:1083–9.
56. Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. *Ann Intern Med* **2014**; 161:634–8.
57. Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. *Hepatology* **2015**; 61:1793–7.

58. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis* **2016**; 16:797–808.
59. US Centers for Disease Control and Prevention. Viral hepatitis surveillance report—United States, 2020, hepatitis C. Published September 2022. Available at: <https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm>. Accessed 19 November 2022.
60. Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet acute HCV IV): an open-label, single-arm, phase 2 study. *Lancet Infect Dis* **2017**; 17:215–22.
61. Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV co-infection: an open-label, single-arm trial. *Lancet Gastroenterol Hepatol* **2017**; 2:347–53.
62. Martinello M, Orkin C, Cooke G, et al. Short-duration pan-genotypic therapy with glecaprevir/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. *Hepatology* **2020**; 72:7–18.
63. Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. *J Hepatol* **2021**; 75:829–39.
64. AASLD-IDS A HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDS recommendations for testing, managing, and treating hepatitis C virus infection. *Clin Infect Dis* **2018**; 67:1477–92.
65. American College of Obstetricians and Gynecologists. Practice advisory: routine hepatitis C virus screening in pregnant individuals. Reaffirmed October 2022. Available at: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/05/routine-hepatitis-c-virus-screening-in-pregnant-individuals>. Accessed 25 November 2022.
66. Dotters-Katz SK, Kuller JA, Hughes BL. Society for Maternal-Fetal Medicine consult series #56: hepatitis C in pregnancy—updated guidelines: replaces consult number 43, November 2017. *Am J Obstet Gynecol* **2021**; 225:B8–B18.
67. Kushner T, Lange M, Sperling R, Dieterich D. Treatment of women with hepatitis C diagnosed in pregnancy: a co-located treatment approach. *Gastroenterology* **2022**; 163:1454–6.e1.
68. Zeng QL, Yu ZJ, Lv J, et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: a case series study. *J Med Virol* **2022**; 94:4548–53.
69. AbdAllah M, Alboraei M, Abdel-Razek W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: real-life data from an Egyptian cohort. *Liver Int* **2021**; 41:1494–7.
70. Chappell CA, Scarsi KK, Kirby BJ, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. *Lancet Microbe* **2020**; 1:e200–e8.
71. Yattoo GN. Treatment of chronic hepatitis C with ledipasvir/sofosbuvir combination during pregnancy [abstract]. *Hepatol Int* **2018**; 12:S292–3.
72. Malik F, Bailey H, Chan P, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. *JHEP Rep* **2021**; 3:100227.
73. Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. *Lancet Gastroenterol Hepatol* **2020**; 5: 374–92.
74. Rossi RM, Wolfe C, Brokamp R, et al. Reported prevalence of maternal hepatitis C virus infection in the United States. *Obstet Gynecol* **2020**; 135:387–95.
75. Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization—United States, 2000–2015. *MMWR Morb Mortal Wkly Rep* **2019**; 68:833–8.
76. Schillie SF, Canary L, Koneru A, et al. Hepatitis C virus in women of childbearing age, pregnant women, and children. *Am J Prev Med* **2018**; 55:633–41.
77. Koneru A, Nelson N, Hariri S, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission—United States and Kentucky, 2011–2014. *MMWR Morb Mortal Wkly Rep* **2016**; 65:705–10.
78. Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients—Wisconsin, 2011–2015. *MMWR Morb Mortal Wkly Rep* **2017**; 66:1136–9.
79. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. *Lancet Gastroenterol Hepatol* **2019**; 4:477–87.
80. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. *Clin Infect Dis* **2014**; 59: 765–73.
81. US Food and Drug Administration. Harvoni prescribing information. Updated April 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205834s017lbl.pdf. Accessed 25 November 2022.
82. US Food and Drug Administration. Solvaldi prescribing information. Updated April 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204671s006lbl.pdf. Accessed 25 November 2022.
83. US Food and Drug Administration. Mavyret prescribing information. Updated June 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209394s014,215110s001lbl.pdf. Accessed 25 November 2022.
84. US Food and Drug Administration. Epclusa prescribing information. Updated June 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208341s017lbl.pdf. Accessed 25 November 2022.
85. Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV: part 2 of the DORA study. *Hepatology* **2021**; 74:19–27.
86. Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. *Hepatology* **2020**; 71:456–62.
87. Jonas MM, Romero R, Sokal EM, et al. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection [abstract 748]. The Liver Meeting. Boston, Massachusetts; **2019**.
88. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. *Hepatology* **2017**; 66:371–8.
89. Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. *Hepatology* **2020**; 2:422–30.
90. Murray KF, Balistreri WF, Bansal S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6–11. *Hepatology* **2018**; 68:2158–66.
91. Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. *Hepatology* **2018**; 68: 1298–307.
92. Ueda Y, Kobayashi T, Ikegami T, et al. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. *J Gastroenterol* **2019**; 54:660–6.
93. Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. *Hepatology* **2017**; 66:1090–101.
94. Agarwal K, Castells L, Müllhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. *J Hepatol* **2018**; 69: 603–7.
95. Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. *Ann Intern Med* **2017**; 166:109–17.
96. Sawinski D, Kaur N, Ajeta A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. *Am J Transplant* **2016**; 16:1588–95.
97. Feng HP, Caro L, Fandozzi CM, et al. Pharmacokinetic interactions between elbasvir/grazoprevir and immunosuppressant drugs in healthy volunteers. *J Clin Pharmacol* **2018**; 58:666–73.
98. US Food and Drug Administration. Zepatier prescribing information. Updated December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208261s007lbl.pdf. Accessed 26 November 2022.
99. US Food and Drug Administration. Vosevi prescribing information. Updated November 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209195s003lbl.pdf. Accessed 26 November 2022.
100. United Network for Organ Sharing. Updated 14 November 2022. Available at: <https://www.unos.org/>. Accessed 14 November 2022.
101. Chang SH, Merzkani M, Lentine KL, et al. Trends in discard of kidneys from hepatitis C viremic donors in the United States. *Clin J Am Soc Nephrol* **2021**; 16:251–61.
102. Cotter TG, Aronsohn A, Reddy KG, Charlton M. Liver transplantation of HCV-viremic donors into HCV-negative recipients in the United States: increasing frequency with profound geographic variation. *Transplantation* **2021**; 105:1285–90.
103. Cotter TG, Paul S, Sandıkçı B, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. *Hepatology* **2019**; 69:2381–95.
104. Madan S, Patel SR, Rahgozar K, et al. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. *J Heart Lung Transplant* **2019**; 38:907–17.

105. Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. *J Am Soc Nephrol* **2019**; 30:1939–51.
106. Madan S, Patel SR, Vlismas P, et al. Increasing multiorgan heart transplantation with hepatitis C virus donors in the current era. *J Heart Lung Transplant* **2021**; 40:1382–6.
107. Sageshima J, Troppmann C, McVicar JP, Santhanakrishnan C, de Mattos AM, Perez RV. Impact of willingness to accept hepatitis C seropositive kidneys among hepatitis C RNA-positive waitlisted patients. *Transplantation* **2018**; 102:1179–87.
108. Sawinski D, Forde KA, Lo Re V 3rd, et al. Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: a retrospective cohort study. *Am J Kidney Dis* **2019**; 73:815–26.
109. Shelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. *Transpl Infect Dis* **2018**; 20:e12829.
110. Alshuler PJ, Helmers MR, Schiavza AR, et al. HCV-positive allograft use in heart transplantation is associated with increased access to overdose donors and reduced waitlist mortality without compromising outcomes. *J Card Fail* **2022**; 28:32–41.
111. Terrault NA, Burton J, Ghobrial M, et al. Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. *Hepatology* **2021**; 73:2110–23.
112. Aqel B, Wijarnprecha K, Pungpaong S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. *J Hepatol* **2021**; 74:873–80.
113. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. *J Am Soc Nephrol* **2020**; 31:2678–87.
114. Gidea CG, Narula N, Reyentovich A, et al. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. *J Heart Lung Transplant* **2020**; 39:1199–207.
115. Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. *N Engl J Med* **2019**; 380:1606–17.
116. Smith DE, Chen S, Fargnoli A, et al. Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors. *Semin Thorac Cardiovasc Surg* **2021**; 33:407–15.
117. Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. *Lancet Gastroenterol Hepatol* **2020**; 5:649–57.
118. Ramirez-Sanchez C, Kozuch J, Shah MM, et al. A pilot trial for prevention of hepatitis C virus transmission from donor to organ transplant recipient with short-course glecaprevir/pibrentasvir. *Open Forum Infect Dis* **2022**; 9:ofac550.
119. Diaz-Castrillon CE, Huckaby LV, Witer L, et al. National trends and outcomes of heart-kidney transplantation using hepatitis C positive donors. *Clin Transplant* **2022**; 36:e14581.
120. Bekki Y, Crismale JF, Myers B, Schiano TD, Florman S. Varying utilization rates but superior outcomes in liver transplantation from hepatitis C-positive donors in the United States: an analysis of the OPTN/UNOS database. *Transplantation* **2022**; 106:1787–98.
121. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. *Am J Transplant* **2017**; 17:2790–802.
122. Kim M, Stern J, Robalino R, et al. Caregiver exposure to hepatitis C virus following transplantation with hepatitis C viremic donor organs: a case series. *Transpl Infect Dis* **2022**; 24:e13775.
123. Karkout KA, Al Sherif S, Hussein Q, Albawardi A, Boobes Y. Possible acute rejection associated with the use of the new anti-hepatitis C virus medications. *Avicenna J Med* **2019**; 9:32–4.
124. Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. *Am J Transplant* **2019**; 19:1380–7.
125. Zaky Z, Herlitz L, Augustine J. The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies. *Transplantation* **2018**; 102:S325.
126. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* **2017**; 5:e1192–e207.
127. Mateu-Gelabert P, Sabounchi NS, Guarino H, et al. Hepatitis C virus risk among young people who inject drugs. *Front Public Health* **2022**; 10:835836.
128. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. *Clin Infect Dis* **2008**; 46:1852–8.
129. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clin Infect Dis* **2013**; 57:S39–45.
130. Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. *J Hepatol* **2018**; 68:402–11.
131. Fraser H, Zibbell J, Hoerger T, et al. Scaling-up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic. *Addiction* **2018**; 113:173–82.
132. Palmateer NE, McAuley A, Dillon JF, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. *Addiction* **2021**; 116:2893–907.
133. Iversen J, Dore GJ, Starr M, et al. Estimating the consensus hepatitis C cascade of care among people who inject drugs in Australia: pre and post availability of direct acting antiviral therapy. *Int J Drug Policy* **2020**; 83:102837.
134. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. *J Addict Med* **2010**; 4:20–6.
135. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. *Ann Intern Med* **2016**; 165:625–34.
136. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *Lancet Gastroenterol Hepatol* **2018**; 3:153–61.
137. Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. *Int J Drug Policy* **2017**; 47:196–201.
138. Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. *Int J Drug Policy* **2018**; 62:74–7.
139. Macías J, Morano LE, Téllez F, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. *J Hepatol* **2019**; 71:45–51.
140. Messina V, Onorato L, Di Caprio G, et al. Directly acting antiviral-based treatment for HCV-infected persons who inject drugs: a multicenter real-life study. *Life (Basel)* **2020**; 11:17.
141. Huang P, Wang Y, Yue M, et al. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: a comprehensive analysis. *Liver Int* **2021**; 41:2341–57.
142. Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. *J Hepatol* **2020**; 72:643–57.
143. Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. *J Hepatol* **2016**; 65:S33–45.
144. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. *Clin Infect Dis* **2016**; 62:683–94.
145. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. *AIDS* **2015**; 29:2335–45.
146. Hoornenborg E, Coyer L, Boyd A, et al. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. *J Hepatol* **2020**; 72:855–64.
147. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. *AIDS* **2017**; 31:1603–10.
148. Pufall EL, Kall M, Shahmanesh M, et al. Sexualized drug use (“chemsex”) and high-risk sexual behaviours in HIV-positive men who have sex with men. *HIV Med* **2018**; 19:261–70.
149. Jin F, Dore GJ, Matthews G, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* **2021**; 6:39–56.
150. Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. *J Hepatol* **2017**; 66:282–7.
151. Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who

- have sex with men after unrestricted access to HCV therapy. *Clin Infect Dis* **2018**; 66:1360–5.
152. Adu PA, Rossi C, Binka M, et al. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men. *Liver Int* **2021**; 41:482–93.
 153. Busschots D, Kremer C, Bielen R, et al. Hepatitis C prevalence in incarcerated settings between 2013–2021: a systematic review and meta-analysis. *BMC Public Health* **2022**; 22:2159.
 154. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. *Hepatology* **2019**; 69:1020–31.
 155. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. *Am J Public Health* **2004**; 94:1218–23.
 156. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. *N Engl J Med* **2014**; 370:1871–4.
 157. Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. *Clin Infect Dis* **2005**; 41:177–86.
 158. Rich JD, Chandler R, Williams BA, et al. How health care reform can transform the health of criminal justice-involved individuals. *Health Aff (Millwood)* **2014**; 33:462–7.
 159. Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The importance of prisons in achieving hepatitis C elimination: insights from the Australian experience. *Viruses* **2022**; 14:497.
 160. He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. *Ann Intern Med* **2016**; 164:84–92.
 161. MacDonald R, Akiyama MJ, Kopelow A, et al. Feasibility of treating hepatitis C in a transient jail population. *Open Forum Infect Dis* **2017**; 4:ofx142.
 162. Spaulding AS, Kim AY, Harzke AJ, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. *Top Antivir Med* **2013**; 21:27–35.
 163. Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C screening of the “birth cohort” (born 1945–1965) and younger inmates of New York City jails. *Am J Public Health* **2016**; 106:1276–7.
 164. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. *J Public Health (Oxf)* **2016**; 38:130–7.
 165. Schoenbachler BT, Smith BD, Seña AC, et al. Hepatitis C virus testing and linkage to care in North Carolina and South Carolina jails, 2012–2014. *Public Health Rep* **2016**; 131 Suppl 2:98–104.
 166. de la Flor C, Porsa E, Nijhawan AE. Opt-out HIV and hepatitis C testing at the Dallas County Jail: uptake, prevalence, and demographic characteristics of testers. *Public Health Rep* **2017**; 132:617–21.
 167. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. *Ann Intern Med* **2014**; 161:546–53.
 168. Ogawa E, Chien N, Kam L, et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. *JAMA Intern Med* **2023**; 183:97–105.
 169. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. *N Engl J Med* **2014**; 370:2063–6.